BioMarin Pharma (BMRN) Misses Q2 EPS by 5c, Revenue Beats

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NRIX
6. SUNS
7. CRDO
8. OIG
9. AMAT
10. SPY

Go back to BioMarin Pharma (BMRN) Misses Q2 EPS by 5c, Revenue Beats

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $108 at BMO Capital

August 5, 2020 9:46 AM EDT

BMO Capital analyst George Farmer raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $108.00 (from $94.00) while maintaining a Market Perform rating.

The analyst commented, "Following model adjustments, we increase our PT to $108 from $94 and maintain our Market Perform rating ahead... More